How Do I Refer My Patient?

Eligibility Criteria

  1. Age: 18+ years old. 

  2. Histological diagnosis of prostate adenocarcinoma with no evidence of metastatic disease on staging investigations (if indicated). 

  3. Intermediate risk prostate cancer as defined by clinical stage cT2 OR Gleason Sum 3+4 = 7 (International Society of Urological Pathology (ISUP) grade group 2) OR Prostate-specific antigen test (PSA) 10-20 ng/mL. 

  4. Fit for radical treatment (either surgery or radiation) at the time of diagnosis. 

  5. Estimated life expectancy > 10 years. 

  6. Formalin-fixed, paraffin-embedded tissue cores are available for genomic testing. 

Exclusion Criteria

  1. Unwilling to accept active surveillance as an initial management strategy. 

  2. The presence of any variant prostate cancer histology (ductal, small cell, sarcomatoid, urothelial, squamous/adenosquamous carcinoma and basal cell carcinoma). 

  3. The presence of high-risk pattern 4 growth patterns (in the pattern 4 component of Gleason 3+4 disease), namely intraductal carcinoma or large cribriform pattern. 

  4. Unable or unwilling to provide informed consent. 

Participating Sites

  • Krupa Mistry

    Department of surgeryLevel 10, VCCC, 305 Grattan St

    The University of Melbourne, Victoria 3010 Australia

    Email: krupa.mistry@unimelb.edu.au

Does this apply to you?

Contact Us